FDC to acquire ‘ENTEROPLUS’ from GlaxoSmithKline Pharmaceuticals

18 Oct 2019 Evaluate

FDC has entered into definitive documents (including a trademark assignment deed) on October 16, 2019 with GlaxoSmithKline Pharmaceuticals (GSK) for acquiring the registered Trademark ‘ENTEROPLUS’ from GSK. The Company would have acquired all the rights of this Trademark/Brand 'ENTEROPLUS'.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

378.50 3.00 (0.80%)
22-Jan-2026 15:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1635.00
Dr. Reddys Lab 1218.90
Cipla 1372.00
Zydus Lifesciences 886.00
Lupin 2167.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×